Latest Salus Therapeutics News
Aug 9, 2011
Tweet Salt Lake City-based MediConnect Global, the developer of medical health records retrieval software, said today that it has tapped Dinesh Patel for its board of directors. Patel is a well known Utah entrepreneur and investor, and was a co-founder of vSpring Capital, co-founder and CEO of Theratech, and also founded Ashni Naturaceuticals and Salus Therapeutics. Other board members at MediConnect include James Lee Sorenson, Alan Hall, Charles Johnson of Leavitt Partners, and Intermountain Healthcare's Scott Parker.
Salus Therapeutics Frequently Asked Questions (FAQ)
When was Salus Therapeutics founded?
Salus Therapeutics was founded in 1999.
Where is Salus Therapeutics's headquarters?
Salus Therapeutics's headquarters is located at Salt Lake City.
What is Salus Therapeutics's latest funding round?
Salus Therapeutics's latest funding round is Acquired.
How much did Salus Therapeutics raise?
Salus Therapeutics raised a total of $4.25M.
Who are the investors of Salus Therapeutics?
Investors of Salus Therapeutics include Genta, WS Investments, vSpring Capital and Pelion Venture Partners.
Who are Salus Therapeutics's competitors?
Competitors of Salus Therapeutics include AVEO Oncology, Cevec Pharmaceuticals, Acura Pharmaceuticals, Esperance Pharmaceuticals, Angstrom Pharmaceuticals and 7 more.
Compare Salus Therapeutics to Competitors
Oxyrane is a biopharmaceutical company dedicated to the development of biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases.
Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).
The company are a technology development and licensing firm with a strong focus on robotics and machine intelligence applications and their integration into industries such as pharmaceuticals and health care. The company take great pride in the company's diverse and knowledgeable staff, who make such ventures possible. Wrightwood Technologies Inc. aims to provide both the public and private sectors with technologies and services that improve efficiency, increase production, reduce costs, eliminate waste, and improve societies' over-all quality of life.
Locus Pharmaceuticals is a company focused on the biotechnology sector, specifically in the area of protein and antibody discovery. The company offers a range of products including proteins, mouse monoclonals, and rabbit antibodies, which are used in various research and scientific applications. The primary customers of Locus Pharmaceuticals are likely to be in the research and healthcare sectors. It was founded in 1999 and is based in Blue Bell, Pennsylvania.
Promoter Neurosciences LLC develops therapeutic compounds to treat stress, anxiety, and depressive disorders through genetic regulation of the CRF systems.
Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.